Alpha 2.0
Login Register
» Authors » D Pectasides

D Pectasides

Explore the profile of D Pectasides including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 125
Citations 1522
Followers 0
Related Specialties
Oncology
Hematology
Pharmacology
Top 10 Co-Authors
G Fountzilas
T Economopoulos
G Aravantinos
A Athanassiou
D Skarlos
E Pectasides
D Bafaloukos
H P Kalofonos
P Kosmidis
E Samantas
Published In
Ann Oncol
Anticancer Res
Am J Clin Oncol
Oncology
Br J Cancer
Affiliations
Soon will be listed here.
Recent Articles
1.
The role of tenofovir in preventing and treating hepatitis B virus (HBV) reactivation in immunosuppressed patients. A real life experience from a tertiary center
Koskinas J, Deutsch M, Adamidi S, Skondra M, Tampaki M, Alexopoulou A, et al.
Eur J Intern Med . 2014 Jul; 25(8):768-71. PMID: 25037900
Introduction/aim: Patients who present HBV reactivation during immunosuppressive treatment are prone to develop life threatening decompensation of the liver function, therefore prophylaxis and treatment are strongly recommended. So far there...
2.
The usefulness of transient elastography in the assessment of patients with HBeAg-negative chronic hepatitis B virus infection
Papatheodoridis G, Manolakopoulos S, Margariti A, Papageorgiou M, Kranidioti H, Katoglou A, et al.
J Viral Hepat . 2014 Apr; 21(7):517-24. PMID: 24750382
Histological severity is often mandatory for the management of HBeAg-negative chronic HBV patients. We evaluated the performance of transient elastography (TE) in this setting. We included 357 untreated HBeAg-negative patients...
3.
Cirrhosis but not neutropenia is associated with the development of infection in patients with chronic hepatitis C undergoing treatment with pegylated interferon-alpha and ribavirin
Striki A, Manolakopoulos S, Deutsch M, Mela M, Kalafateli M, Schini M, et al.
J Viral Hepat . 2013 Nov; 21(9):624-32. PMID: 24224747
Peginterferon-alpha (PegIFNa) frequently causes neutropenia, mainly due to bone marrow suppression. The aim of this study was to explore factors that are associated with infections during antiviral treatment. We analysed...
4.
Vascular endothelial growth factor polymorphisms and clinical outcome in patients with metastatic breast cancer treated with weekly docetaxel
Koutras A, Kotoula V, Papadimitriou C, Dionysopoulos D, Zagouri F, Kalofonos H, et al.
Pharmacogenomics J . 2013 Sep; 14(3):248-55. PMID: 24061601
The aim of the study was to evaluate the association of vascular endothelial growth factor (VEGF) genotypes with treatment efficacy in a phase II trial. This study evaluated weekly docetaxel,...
5.
Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03)
Bamias A, Dafni U, Karadimou A, Timotheadou E, Aravantinos G, Psyrri A, et al.
Ann Oncol . 2012 Nov; 24(4):1011-7. PMID: 23136231
Background: The combinations of methotrexate, vinblastine, Adriamycin, cisplatin (Pharmanell, Athens, Greece) (MVAC) or gemcitabine, cisplatin (GC) represent the standard treatment of advanced urothelial cancer (UC). Dose-dense (DD)-MVAC has achieved longer...
6.
Prognostic significance of RACGAP1 mRNA expression in high-risk early breast cancer: a study in primary tumors of breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial
Pliarchopoulou K, Kalogeras K, Kronenwett R, Wirtz R, Eleftheraki A, Batistatou A, et al.
Cancer Chemother Pharmacol . 2012 Oct; 71(1):245-55. PMID: 23096218
Purpose: RACGAP1 is a Rac GTPase-activating protein involved in cell growth regulation, cell transformation and metastasis. The aim of the present study was to explore the prognostic and/or predictive significance...
7.
Array-based pharmacogenomics of molecular-targeted therapies in oncology
Sanoudou D, Mountzios G, Arvanitis D, Pectasides D
Pharmacogenomics J . 2012 Jan; 12(3):185-96. PMID: 22249357
The advent of microarrays over the past decade has transformed the way genome-wide studies are designed and conducted, leading to an unprecedented speed of acquisition and amount of new knowledge....
8.
Prognostic significance of UBE2C mRNA expression in high-risk early breast cancer. A Hellenic Cooperative Oncology Group (HeCOG) Study
Psyrri A, Kalogeras K, Kronenwett R, Wirtz R, Batistatou A, Bournakis E, et al.
Ann Oncol . 2011 Nov; 23(6):1422-7. PMID: 22056852
Background: The ubiquitin-proteasome system (UPS) plays a pivotal role in tumorigenesis. Components of the UPS have recently been implicated in breast cancer progression. In the present study, we sought to...
9.
Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III...
Skarlos P, Christodoulou C, Kalogeras K, Eleftheraki A, Bobos M, Batistatou A, et al.
Cancer Chemother Pharmacol . 2011 Sep; 69(2):533-46. PMID: 21901395
Purpose: It is well recognized that breast cancer is a heterogeneous disease. The purpose of the current study was to classify patients according to the immunohistochemical phenotype of their tumors...
10.
Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab
Koutras A, Antonacopoulou A, Eleftheraki A, Dimitrakopoulos F, Koumarianou A, Varthalitis I, et al.
Pharmacogenomics J . 2011 Aug; 12(6):468-75. PMID: 21844885
The aim of the study was to evaluate the association of vascular endothelial growth factor (VEGF) genotypes with treatment efficacy in a randomized trial. This study compared two chemotherapy regimens...